Tlwm Boosts Holdings in AstraZeneca PLC $AZN

by · The Markets Daily

Tlwm grew its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 1.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,428 shares of the company’s stock after purchasing an additional 169 shares during the period. Tlwm’s holdings in AstraZeneca were worth $1,218,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Larson Financial Group LLC raised its stake in shares of AstraZeneca by 297.9% during the first quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock valued at $28,000 after purchasing an additional 289 shares during the period. Richardson Financial Services Inc. increased its stake in shares of AstraZeneca by 59.8% in the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after buying an additional 149 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in shares of AstraZeneca in the first quarter worth $29,000. Costello Asset Management INC bought a new stake in shares of AstraZeneca in the first quarter worth $29,000. Finally, Maseco LLP bought a new stake in shares of AstraZeneca in the second quarter worth $34,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

AZN has been the subject of a number of research analyst reports. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research note on Wednesday, July 9th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $86.00.

Get Our Latest Research Report on AZN

AstraZeneca Trading Down 0.3%

NASDAQ AZN opened at $84.83 on Thursday. The firm has a market capitalization of $263.09 billion, a PE ratio of 31.89, a price-to-earnings-growth ratio of 1.56 and a beta of 0.36. AstraZeneca PLC has a one year low of $61.24 and a one year high of $86.57. The company has a 50-day simple moving average of $79.82 and a 200-day simple moving average of $73.69. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86.

AstraZeneca (NASDAQ:AZN – Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, hitting the consensus estimate of $1.09. The firm had revenue of $14.46 billion for the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. AstraZeneca’s quarterly revenue was up 16.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.24 earnings per share. On average, equities analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Investors of record on Friday, August 8th were paid a dividend of $0.505 per share. The ex-dividend date was Friday, August 8th. This represents a yield of 200.0%. AstraZeneca’s dividend payout ratio is 37.97%.

About AstraZeneca

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Stories